Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma

Rhea-AI Summary

Applied BioMath has announced a collaboration with SpringWorks Therapeutics (SWTX) to develop a systems pharmacology model for multiple myeloma. This model will analyze the interactions between nirogacestat, an oral selective small molecule gamma secretase inhibitor, and agents targeting B-cell maturation antigen (BCMA). Todd Shearer, PhD, emphasized the goal of enhancing the understanding of pharmacodynamic interactions to streamline therapy advancements. Applied BioMath aims to leverage its modeling expertise to support drug research and development success.

Positive

• Collaboration with SpringWorks Therapeutics to develop a pharmacology model for multiple myeloma.
• Targeting pharmacodynamic interactions could accelerate the development of therapies.
• Applied BioMath's expertise in systems pharmacology may improve research outcomes.

Negative

• None.

CONCORD, Mass., Nov. 1, 2022 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their collaboration with SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, for the development of a systems pharmacology model in multiple myeloma. 

In this collaboration, Applied BioMath is developing a model of SpringWorks' investigational oral selective small molecule gamma secretase inhibitor (GSI), nirogacestat, in combination with an agent that targets B-cell maturation antigen (BCMA) for the treatment of multiple myeloma. 

"Our goal is to lead the scientific understanding of the pharmacodynamic interactions between nirogacestat and BCMA-targeted agents in order to advance therapies more efficiently to help patients with multiple myeloma," said Todd Shearer, PhD, Vice President, Clinical Pharmacology at SpringWorks Therapeutics. "We are pleased to work with Applied BioMath given their expertise in building systems pharmacology models for biopharmaceutical companies and we look forward to working with them to further advance our BCMA efforts."

Applied BioMath offers software and services to help de-risk and accelerate drug R&D. Their solutions, which focus on quantitatively integrating knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms, are leveraged across the entire R&D spectrum from early research through to clinical trials. Their approach involves working with clients to develop the appropriate mathematical strategy for each unique project, with common strategies encompassing systems pharmacology, mechanistic modeling. bioinformatics, biosimulation, and clinical pharmacology.

"Applying mathematical and engineering approaches to translational medicine allows us to integrate knowledge about the therapeutic with an understanding of its mechanism of action in the context of human disease mechanisms," said John Burke, PhD, Co-founder, President and CEO at Applied BioMath. "This enables project teams developing therapeutics to answer more questions earlier and advance programs more efficiently."

To learn more about Applied BioMath, visit www.appliedbiomath.com. 

About Applied BioMath

Founded in 2013, Applied BioMath's mission is to revolutionize drug invention. Applied BioMath applies biosimulation, including quantitative systems pharmacology, PKPD, bioinformatics, machine learning, clinical pharmacology, and software solutions to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk therapeutic research and development. Their approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through all phases of clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their therapeutic, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic to increase likelihood of clinical concept and proof of mechanism, and decrease late stage attrition rates. For more information about Applied BioMath and its services and software, visit www.appliedbiomath.com.

Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/applied-biomath-llc-announces-collaboration-with-springworks-therapeutics-inc-for-systems-pharmacology-modeling-in-multiple-myeloma-301664970.html

SOURCE Applied BioMath, LLC

FAQ

What is the collaboration between Applied BioMath and SpringWorks Therapeutics about?

The collaboration focuses on developing a systems pharmacology model for multiple myeloma to enhance understanding of drug interactions.

What is nirogacestat in relation to this collaboration?

Nirogacestat is an investigational oral selective small molecule gamma secretase inhibitor being studied in combination with agents targeting BCMA.

How might this collaboration impact SpringWorks Therapeutics (SWTX)?

The collaboration could lead to more efficient drug development processes and potentially better therapeutic options for multiple myeloma.

When was the collaboration between Applied BioMath and SpringWorks Therapeutics announced?

The collaboration was announced on November 1, 2022.